The COVID-19 pipeline: An unprecedented global clinical development effort

Posted by Kristyn Feldman on Mon, Apr 06, 2020

Parul Rewari, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

The global COVID-19 pandemic continues to dominate headlines, including near constant updates from the pharma industry and academic clinical researchers the world over. Last week, we looked at the clinical-stage programs aimed to address the novel coronavirus. This week, we have expanded our analysis to include a wider range of clinical programs, including phase IV studies, and additional sources of data regarding this quickly evolving landscape.


>
Read More

COVID-19 Clinical Development: What's in the Pipeline to Address the SARS-CoV-2 Pandemic?

Posted by Kristyn Feldman on Tue, Mar 24, 2020

Parul Rewari, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

As nations around the globe are hit hard by the novel coronavirus pandemic, many are asking the same question: What treatments or preventions are in the pipeline that may address COVID-19? Researchers the world over have launched numerous research, preclinical and clinical-stage programs in an effort to identify vaccines and treatments that can tackle the virus or to find treatments that mediate the downstream effects of the virus.


>
Read More

Clinical Development Risks and Issues in a COVID-19 World

Posted by Jonathan Rowe on Fri, Mar 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).


>
Read More

AI & Real-World Data: A Perfect Union

Posted by Arun Shastri on Mon, Jan 27, 2020

This blog post is the seventh in a series on the impact that AI will have on different business aspects of pharma.

Real world data (RWD) is as old as data itself. It was relatively useless, however, until it was digitized. And then once it was digitized, we struggled to analyze so much data at scale with any kind of efficiency.

Enter our ability to store and analyze large volumes of data and advancements in data science, algorithms and technology. With the help of AI, it’s now possible to truly leverage RWD and begin to understand patient populations in holistic ways that have so far eluded pharmaceutical companies. It’s accelerating the use of evidence across healthcare to support the focus on patient health outcomes.


>
Read More

AI & Clinical Trials: Poised for Disruption

Posted by Arun Shastri on Wed, Sep 11, 2019

This blog post is the third in a series on the impact that AI will have on different business aspects of pharma.

We always tell our clients to start small with AI. As Pratap Khedkar shared in my first interview, it’s important to start with clear, specific use cases. For some aspects of the business, it may take some time to carefully consider what these specific use cases are and what opportunities AI can create. Clinical trials present no such difficulties. The opportunities to improve efficiencies are numerous and clear, and AI has begun to make an impact. The industry is aware of the inefficiencies that abound in clinical trial design and execution and is eager to solve them.


>
Read More